An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults
Information source: Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Polypharmacy; Incontinence; Insomnia; Anxiety
Intervention: knowledge transfer tool (Behavioral)
Phase: Phase 4
Status: Terminated
Sponsored by: Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal Official(s) and/or principal investigator(s): Cara Tannenbaum, MD, Principal Investigator, Affiliation: Centre de recherche de l'Institut universitaire de gériatrie de Montréal
Summary
An educational intervention targeting community-dwelling older adults will lead to a
reduction in potentially inappropriate prescriptions (e. g. benzodiazepines, oxybutynin).
Cessation of potentially inappropriate medications (e. g. benzodiazepines, oxybutynin)will
lead to improved cognitive outcomes in older adults.
Clinical Details
Official title: The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Primary outcome: Complete discontinuation of the targeted potentially inappropriate medication (e.g. benzodiazepines, oxybutynin)
Secondary outcome: Cognitive functionSleep efficiency incontinence-related self-efficacy frequency of urinary incontinence episodes
Detailed description:
This study tests the effectiveness of a knowledge transfer tool for empowering patients to
engage in collaborative discontinuation of potentially inappropriate medication with their
pharmacist and/or physician
Eligibility
Minimum age: 65 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 65 year old human adults
- who fill a prescription for at least 5 medications
- community dwelling
- chronic use (3 months or longer) of at least one potentially inappropriate medication
(e. g. benzodiazepine, oxybutynin)
Exclusion Criteria:
- patients with severe mental illness, dementia and epilepsy
- concomitant consumption of any other antipsychotic medication (including lithium,
olanzapine, clozapine, quetiapine, risperidone, haloperidol etc.)
- concomitant consumption of any antiepileptic (including carbamazepine, valproate,
gabapentin, lamotrigine, topiramate, oxcarbazepine etc.)
- concomitant consumption of a cholinesterase inhibitor or memantine
Locations and Contacts
Le Groupe Jean Coutu Inc., Longueuil, Quebec J4G 1S8, Canada
Additional Information
Starting date: June 2010
Last updated: May 14, 2013
|